HDL Diagnostics, Inc

HDL Diagnostics, Inc. (“HDL Dx”) was an early stage diagnostics company focused on cardiovascular disease (CVD). The company had filed a provisional patent application on its technology: tests to assess the functional status of high density lipoproteins (HDL). HDL, commonly called the “good cholesterol,” is a complex biological particle composed of multiple proteins and lipids that mediate several functions including inhibiting arterial inflammation and removing excess cholesterol. Recent peer-reviewed articles suggest that HDL dysfunction, which can occur in individuals who have “normal” cholesterol levels, leads to CVD. HDL Dx provided a new technology to comprehensively assess the multiple functions of HDL as a means of identifying individuals who are at increased risk of CVD. We want to thank all of our colleagues, advisors, and investors for their partnership in HDL DX. The journey has come to an end this year (December 2024). - HDL Diagnostics Management Team